Osaka, 14^th January 2025 – PSI CRO, a Swiss-based global full-service contract research organization, today announced further expansion in Japan, with the opening of the second office located on Level 18 of the Hilton Plaza West Office Tower in Umeda, Kita-ku, Osaka.

Japan is a vital market for pivotal clinical trials. In early 2025, PSI opened its first Japanese office in Tokyo and appointed Sayaka Kaji as Country Manager for Japan. By adding an Osaka location, PSI brings sponsors closer to experienced local teams and the local PSI team closer to the established site networks.

As clinical research grows more complex – with no end to the complexity in sight – Japan is well placed to benefit from PSI’s distinctive delivery model. With a larger team operating from two strategic locations, PSI brings strong in-country knowledge and established relationships across Japan’s clinical research community, helping sponsors move faster with delivery that’s predictable, responsive, and grounded in local experience.

Sayaka Kaji says, “PSI’s approach means we adapt rapidly to our clients’ needs and market changes. I’m proud of what we achieved in 2025: we hit our milestones and grew our team significantly. The new office in Osaka will ensure that sponsors in Japan can count on the same standard of excellence that defines PSI worldwide, with local experts who understand the region’s unique challenges and bring proven solutions to every project. I feel the spirit of 不撓不屈 (undaunted determination and indomitable will) in each team member as we strive towards our ambitious goals.”

From Tokyo to Osaka, PSI’s purpose remains clear: deliver clinical trials on time, no matter geography or complexity.

PSI’s further expansion and continued growth in Japan follows recent office expansions in Asia-Pacific, including South Korea, Singapore, China, Taiwan, India, Australia, and New Zealand, where PSI operates with dedicated full-time office-based staff.

To learn more about PSI’s capabilities in Japan, please contact us today.

ENDS

​

For further information, please contact:

PSI Ashley Collins T: +1 919-972-9572 E: ashley.stufanocollins@psi-cro.com 

Sciad Communications, Media Relations Jasmin Shearan, Maria Taylor E: pressteam@sciad.com  T: +44 2034 057892 

Notes for Editors

About PSI 

PSI CRO is a global, full-service contract research organization (CRO) focused on the disciplined delivery of pivotal clinical trials. The company’s defining operational metric is on-time trial delivery, which has consistently remained above 90% in 2025 — reflecting the strength of its teams, processes, and site relationships.

PSI specializes in phase II and phase III clinical trials in oncology, hematology, gastroenterology, autoimmune diseases, infectious diseases, neurology, and other complex indications. The company is particularly experienced in trials requiring advanced operational coordination, including platform and umbrella designs, targeted immunotherapies, radiopharmaceuticals, and cell and gene therapies.

In 2025, PSI celebrated its 30th year as the only fully independent and privately owned mid-sized CRO. The company employs over 3,200 professionals across 56 countries as of December 19, 2025. PSI’s global headquarters are located in Zug, Switzerland.

For more information, visit www.psi-cro.com.